RxDoctor Payments Data

Richard Sturm

Atlanta, GANPI 1699738955

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,565 of the $10,706 with a category attached, or 61.3%. AbbVie accounts for 62.1% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $3,231 and has fallen 85.3% since, to $475 in 2025.

$10,706in general payments, 2019–2025

Across 367 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Merz North America, Inc.$1K
  • Pfizer$459
  • Sanofi$337
  • Novartis$301
  • Regeneron Healthcare Solutions, Inc.$258
  • plus $1K from 20 others

What the payments were for

  • Speaking & faculty fees$4,04038%
  • Food & beverage$6,56561%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →